Treatment of hemiplegic migraine with Anti-CGRP monoclonal antibodies: a retrospective study

Treatment of hemiplegic migraine with Anti-CGRP monoclonal antibodies: a retrospective study - Treatment of hemiplegic migraine with Anti-CGRP monoclonal antibodies: a retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048097

Enrollment

Registered

2022-06-18

Start date

2022-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemiplegic migraine

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemiplegic migraine cases treated with CGRP-related antibodies

Exclusion criteria

Exclusion criteria: Treatment duration is less than 3 months No motor symptoms at baseline

Design outcomes

Primary

Measure	Time frame
changes from baseline in monthly headache days	—

Countries

Japan

Contacts

Public ContactDaisuke DANNO

Tominaga Hospital Headache center, Department of neurology

daisuke_danno@yahoo.co.jp06-6568-1601

Outcome results